Xenon Pharmaceuticals Inc. (XENE) shareholders
Close on Nov 17, 2026Market cap $3.76BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (11.50%) | 11,136,649 | 11.50% | 13G (passive) amendment | Sep 30, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (11.50%) | 8,824,363 | 11.50% | 13G (passive) amendment | Jun 30, 2025 |
| T. Rowe Price Investment Management, Inc. | 7,905,757 | 8.20% | 13G (passive) | Sep 30, 2026 |
| Behzad Aghazadeh Joint filing with Avoro Capital Advisors LLC (6.26%) | 5,777,777 | 6.26% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 4,757,709 | 6.20% | 13G (passive) | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of XENE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 9,647,998 | 9.96% | $582.35M | −1,170,493 | 0.03% |
| BlackRock, Inc. | 7,522,482 | 7.77% | $454.06M | +1,882,364 | 0.01% |
| Avoro Capital Advisors LLC | 5,777,777 | 5.97% | $348.75M | – | 3.13% |
| Polar Capital Holdings Plc | 4,570,556 | 4.72% | $275.88M | +165,244 | 0.65% |
| Driehaus Capital Management LLC | 4,418,557 | 4.56% | $266.70M | −73,096 | 1.55% |
| Jupiter Topco LLC | 4,186,519 | 4.32% | $252.67M | New | 0.10% |
| Price T Rowe Associates Inc /Md/ | 3,248,219 | 3.35% | $196.06M | +1,918,628 | 0.02% |
| JPMorgan Chase & Co | 2,617,360 | 2.70% | $157.38M | +693,750 | 0.01% |
| Capital International Investors | 2,361,639 | 2.44% | $142.55M | −313,088 | 0.03% |
| T. Rowe Price Investment Management, Inc. | 2,168,581 | 2.24% | $130.90M | +1,216,626 | 0.09% |
| State Street Corp | 1,969,629 | 2.03% | $118.89M | +249,096 | 0.00% |
| Two Sigma Investments, LP | 1,642,848 | 1.70% | $99.16M | +1,036,763 | 0.07% |
| Deerfield Management Company, L.P. (Series C) | 1,615,696 | 1.67% | $97.52M | – | 1.02% |
| Affinity Asset Advisors, LLC | 1,595,000 | 1.65% | $96.27M | −80,000 | 4.35% |
| Alliancebernstein L.P. | 1,562,276 | 1.61% | $90.85M | +158,979 | 0.03% |
| Westfield Capital Management Co LP | 1,507,294 | 1.56% | $90.98M | +105,811 | 0.30% |
| Franklin Resources Inc | 1,437,712 | 1.48% | $86.78M | +157,135 | 0.02% |
| Wellington Management Group Llp | 1,425,492 | 1.47% | $86.04M | −3,404,149 | 0.01% |
| Citadel Advisors LLC | 1,401,242 | 1.45% | $84.58M | −1,251,748 | 0.01% |
| Geode Capital Management, LLC | 1,370,114 | 1.41% | $82.69M | +277,182 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 315 | 101M | 100.0% | 50 / 125 | 87 / 22 | 20M | 15M |
| Q1 2026 | 290 | 100M | 100.0% | 81 / 124 | 60 / 33 | 24M | 7M |
| Q4 2025 | 246 | 85M | 87.3% | 51 / 82 | 74 / 22 | 10M | 11M |
| Q3 2025 | 219 | 86M | 88.5% | 35 / 68 | 71 / 20 | 10M | 7M |
| Q2 2025 | 206 | 83M | 86.0% | 42 / 76 | 56 / 40 | 19M | 13M |
| Q1 2025 | 206 | 77M | 79.3% | 20 / 70 | 72 / 23 | 7M | 6M |
| Q4 2024 | 209 | 76M | 78.8% | 29 / 65 | 70 / 21 | 6M | 5M |
| Q3 2024 | 203 | 76M | 78.4% | 15 / 74 | 63 / 24 | 10M | 7M |
| Q2 2024 | 213 | 75M | 77.5% | 21 / 78 | 71 / 27 | 6M | 6M |
| Q1 2024 | 220 | 75M | 77.7% | 36 / 79 | 67 / 19 | 8M | 6M |
| Q4 2023 | 204 | 73M | 75.6% | 46 / 87 | 50 / 19 | 18M | 8M |
| Q3 2023 | 180 | 63M | 64.5% | 22 / 72 | 51 / 15 | 8M | 7M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
321 funds held XENE in Q2 2026, 14% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of XENE | Value | % of fund | As of |
|---|---|---|---|---|---|
| SMALLCAP World Fund Inc | 3,124,659 | 3.23% | $188.60M | 0.20% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,519,578 | 2.60% | $152.08M | 0.18% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 1,937,648 | 2.00% | $106.05M | 0.04% | May 31, 2026 |
| T. Rowe Price Capital Appreciation Fund | 1,274,673 | 1.32% | $76.94M | 0.11% | Jun 30, 2026 |
| Select Health Care Portfolio | 1,150,000 | 1.19% | $62.94M | 1.09% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 1,072,877 | 1.11% | $67.24M | 0.20% | Jul 31, 2026 |
| JPMorgan Mid Cap Growth Fund | 962,101 | 0.99% | $58.07M | 0.44% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 906,147 | 0.94% | $54.70M | 0.35% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 902,587 | 0.93% | $54.48M | 0.37% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 853,241 | 0.88% | $51.50M | 0.52% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 780,761 | 0.81% | $48.93M | 0.56% | Jul 31, 2026 |
| Small Cap Growth Fund | 668,917 | 0.69% | $41.92M | 0.75% | Jul 31, 2026 |
| iShares Biotechnology ETF | 642,923 | 0.66% | $38.81M | 0.43% | Jun 30, 2026 |
| Fidelity Stock Selector Small Cap Fund | 591,185 | 0.61% | $37.05M | 0.50% | Jul 31, 2026 |
| Federated Hermes Kaufmann Fund | 522,500 | 0.54% | $32.75M | 0.66% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ian Mortimer | PRESIDENT & CEO, Director | 64,223 | 0.07% | Oct 1, 2026 |
| Thomas Patrick Kelly | Chief Financial Officer | 22,500 | 0.02% | Oct 16, 2026 |
| Christopher John Kenney | Chief Medical Officer | 2 | 0.00% | Aug 31, 2026 |
| Andrea DiFabio | Chief Legal Officer | 7,301 | 0.01% | Mar 13, 2026 |
| Darren S. Cline | Chief Commercial Officer | 0 | – | Jan 9, 2026 |
| Sherry Aulin | Chief Financial Officer | 0 | – | Dec 19, 2024 |
| Dawn Svoronos | Director | 31,373 | 0.03% | Sep 3, 2026 |
| Steven Gannon | Director | 1,870 | 0.00% | Aug 13, 2026 |
| Gillian Cannon | Director | 1,455 | 0.00% | Jun 8, 2026 |
| Gary Patou | Director | 29,798 | 0.03% | Jun 8, 2026 |
| Elizabeth A. Garofalo | Director | 2,645 | 0.00% | Jun 3, 2026 |
| Justin D. Gover | Director | 2,645 | 0.00% | Jun 3, 2026 |
| Patrick Machado | Director | 2,645 | 0.00% | Jun 3, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Thomas Patrick Kelly Chief Financial Officer | Oct 15, 2026 | Option exercise | +7,500 | – | – | 22,500 |
| Ian Mortimer PRESIDENT & CEO, Director | Sep 30, 2026 | Buy | +30,000 | $37.38 | $1.12M | 49,923 |
| Thomas Patrick Kelly Chief Financial Officer | Sep 30, 2026 | Buy | +15,000 | $37.32 | $559.74K | 15,000 |
| Dawn Svoronos Director | Sep 1, 2026 | Option exercise | +5,144 | $8.15 | $41.92K | 31,373 |
| Christopher John Kenney Chief Medical Officer | Aug 28, 2026 | Sale(10b5-1 plan) | −700 | $60.98 | $42.69K | 2 |
| Christopher John Kenney Chief Medical Officer | Aug 28, 2026 | Sale(10b5-1 plan) | −6,368 | $60.17 | $383.16K | 702 |
| Steven Gannon Director | Aug 11, 2026 | Sale | −10,000 | $64.06 | $640.60K | 1,870 |
| Gary Patou Director | Jun 5, 2026 | Sale(10b5-1 plan) | −1,322 | $53.14 | $70.25K | 24,896 |
| Gillian Cannon Director | Jun 5, 2026 | Sale(10b5-1 plan) | −1,190 | $53.14 | $63.24K | 1,455 |
| Dawn Svoronos Director | Jun 1, 2026 | Tax withholding | −1,416 | $53.41 | $75.63K | 26,229 |
| Dawn Svoronos Director | Jun 1, 2026 | Option exercise | +2,645 | – | – | 27,645 |
| Justin D. Gover Director | Jun 1, 2026 | Option exercise | +2,645 | – | – | 2,645 |
| Patrick Machado Director | Jun 1, 2026 | Option exercise | +2,645 | – | – | 2,645 |
| Steven Gannon Director | Jun 1, 2026 | Option exercise | +2,645 | – | – | 13,286 |
| Steven Gannon Director | Jun 1, 2026 | Tax withholding | −1,416 | $53.41 | $75.63K | 11,870 |
| Gary Patou Director | Jun 1, 2026 | Option exercise | +2,645 | – | – | 26,218 |
| Gillian Cannon Director | Jun 1, 2026 | Option exercise | +2,645 | – | – | 2,645 |
| Elizabeth A. Garofalo Director | Jun 1, 2026 | Option exercise | +2,645 | – | – | 2,645 |
| Steven Gannon Director | May 12, 2026 | Option exercise | +3,500 | $7.38 | $25.83K | 10,641 |
| Christopher John Kenney Chief Medical Officer | Mar 13, 2026 | Sale(10b5-1 plan) | −1,410 | $55.23 | $77.87K | 7,069 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 13, 2026 | Sale(10b5-1 plan) | −7,308 | $55.23 | $403.62K | 19,923 |
| Andrea DiFabio Chief Legal Officer | Mar 13, 2026 | Sale(10b5-1 plan) | −1,342 | $55.23 | $74.12K | 7,301 |
| Christopher John Kenney Chief Medical Officer | Mar 12, 2026 | Option exercise | +3,750 | – | – | 8,479 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 12, 2026 | Option exercise | +12,500 | – | – | 27,231 |
| Andrea DiFabio Chief Legal Officer | Mar 12, 2026 | Option exercise | +3,750 | – | – | 8,643 |
| Christopher John Kenney Chief Medical Officer | Mar 10, 2026 | Sale(10b5-1 plan) | −2,771 | $60.11 | $166.56K | 4,729 |
| Andrea DiFabio Chief Legal Officer | Mar 10, 2026 | Sale(10b5-1 plan) | −2,607 | $60.11 | $156.71K | 4,893 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 10, 2026 | Sale(10b5-1 plan) | −11,269 | $60.11 | $677.38K | 14,731 |
| Christopher John Kenney Chief Medical Officer | Mar 9, 2026 | Option exercise | +7,500 | – | – | 7,500 |
| Andrea DiFabio Chief Legal Officer | Mar 9, 2026 | Option exercise | +7,500 | – | – | 7,500 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Option exercise | +20,000 | – | – | 26,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −65,000 | $62.06 | $4.03M | 6,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Option exercise | +65,000 | $9.44 | $613.60K | 71,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −61,652 | $60.08 | $3.70M | 6,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −43,348 | $59.26 | $2.57M | 72,652 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Option exercise | +105,000 | $4.75 | $498.75K | 111,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −2,449 | $61.26 | $150.03K | 6,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −10,072 | $60.47 | $609.05K | 8,449 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −12,479 | $59.50 | $742.50K | 18,521 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Option exercise | +25,000 | $3.10 | $77.50K | 31,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −21,515 | $60.49 | $1.30M | 6,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −31,694 | $59.88 | $1.90M | 27,515 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −21,791 | $58.81 | $1.28M | 59,209 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Option exercise | +75,000 | $8.40 | $630.00K | 81,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 2, 2026 | Sale(10b5-1 plan) | −2,062 | $44.93 | $92.65K | 6,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 2, 2026 | Option exercise | +40,000 | $7.49 | $299.60K | 46,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 2, 2026 | Sale(10b5-1 plan) | −37,938 | $44.40 | $1.68M | 8,062 |
| Ian Mortimer PRESIDENT & CEO, Director | Dec 8, 2025 | Sale(10b5-1 plan) | −8,820 | $45.59 | $402.10K | 8,010 |
| Ian Mortimer PRESIDENT & CEO, Director | Dec 8, 2025 | Sale(10b5-1 plan) | −2,010 | $46.32 | $93.10K | 6,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Dec 5, 2025 | Sale(10b5-1 plan) | −14,375 | $45.03 | $647.31K | 16,830 |
| Ian Mortimer PRESIDENT & CEO, Director | Nov 28, 2025 | Sale(10b5-1 plan) | −97 | $45.01 | $4.37K | 31,205 |
| Ian Mortimer PRESIDENT, CEO & INTERIM CFO, Director | Oct 1, 2025 | Option exercise | +25,000 | $7.69 | $192.25K | 56,302 |
| Ian Mortimer PRESIDENT, CEO & INTERIM CFO, Director | Oct 1, 2025 | Sale(10b5-1 plan) | −25,000 | $40.16 | $1.00M | 31,302 |
| Steven Gannon Director | Jun 5, 2025 | Sale | −3 | $30.48 | $91 | 7,141 |
| Steven Gannon Director | May 14, 2025 | Option exercise | +5,144 | $12.57 | $64.66K | 7,144 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 27, 2025 | Option exercise | +15,166 | $17.76 | $269.35K | 46,468 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 27, 2025 | Sale(10b5-1 plan) | −1,149 | $41.07 | $47.19K | 31,302 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 27, 2025 | Sale(10b5-1 plan) | −15,166 | $40.46 | $613.62K | 31,302 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 27, 2025 | Option exercise | +1,149 | $17.76 | $20.41K | 32,451 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 24, 2025 | Sale(10b5-1 plan) | −22,468 | $40.20 | $903.21K | 31,302 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Xenon Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 44,640 shares on Oct 7, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Christopher John Kenney Officer | Aug 28, 2026 | 7,068 | $437.72K | Aug 28, 2026 | Restricted and Performance Stock Units |
| Steven Gannon Director | Aug 13, 2026 | 10,000 | $640.55K | Aug 11, 2026 | Open Market Purchase |
| Gary Patou Director | Jun 5, 2026 | 1,322 | $70.05K | Jun 5, 2026 | Restricted Stock Units |
| Gillian Cannon Director | Jun 5, 2026 | 1,190 | $63.06K | Jun 5, 2026 | Restricted Stock Units |
| Ian Mortimer Officer, Director | Mar 13, 2026 | 7,308 | $403.58K | Mar 13, 2026 | Restricted share unit award vesting |
| Andrea DiFabio Officer | Mar 13, 2026 | 1,342 | $74.11K | Mar 13, 2026 | Restricted share unit award vesting |
| Christopher John Kenney Officer | Mar 13, 2026 | 1,410 | $77.87K | Mar 13, 2026 | Restricted share unit award vesting |
| Ian Mortimer Officer, Director | Mar 10, 2026 | 11,269 | $677.36K | Mar 10, 2026 | Performance share unit award vesting |
| Christopher John Kenney Officer | Mar 10, 2026 | 2,771 | $166.56K | Mar 10, 2026 | Performance share unit award vesting |
| Andrea DiFabio Officer | Mar 10, 2026 | 2,607 | $156.70K | Mar 10, 2026 | Performance share unit award vesting |
| Ian Mortimer Officer, Director | Mar 9, 2026 | 270,000 | $16.29M | Mar 9, 2026 | Exercise of Options |
| Ian Mortimer Officer, Director | Jan 2, 2026 | 40,000 | $1.78M | Jan 2, 2026 | Exercise of Options |
| Ian Mortimer Officer, Director | Dec 8, 2025 | 10,830 | $495.25K | Dec 8, 2025 | Exercise of Options |
| Ian Mortimer Officer, Director | Dec 5, 2025 | 14,375 | $647.36K | Dec 5, 2025 | Exercise of Options |
| Ian Mortimer Officer, Director | Dec 1, 2025 | 97 | $4.37K | Nov 28, 2025 | Exercise of Options |
See a number that looks wrong?